Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia

PURPOSE Colony-stimulating factor-3 receptor (CSF3R)-T618I is a recurrent activating mutation in chronic neutrophilic leukemia (CNL) and to a lesser extent in atypical chronic myeloid leukemia (aCML) resulting in constitutive JAK-STAT signaling. We sought to evaluate safety and efficacy of the JAK1/2 inhibitor ruxolitinib in patients with CNL and aCML, irrespective of CSF3R mutation status….

Read the full article here

Source: Journal of Clinical Oncology

Categories: Hem/Oncs

Tweets with this article

Razelle Kurzrock, MD

Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia | Journal of Clinical Oncology https://t.co/Ivt856YsFR

Pattern and the Medical College of Wisconsin Launch New Pilot Study to Assess Detection of Head, Neck and Lung Cancers Through ProSpectral™ Saliva Analysis

REDMOND, Wash., Aug. 21, 2024 (GLOBE NEWSWIRE) — Pattern Computer®, Inc. (“Pattern” or “the Company”) today announced that Pattern and the Medical College of Wisconsin…

Razelle Kurzrock, MD August 21, 2024

Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series

KRAS wild-type (WT) pancreatic ductal adenocarcinoma (PDAC) represents a distinct entity with unique biology. The therapeutic impact of matched targeted therapy in these patients in…

Razelle Kurzrock, MD July 31, 2024

Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series

KRAS wild-type (WT) pancreatic ductal adenocarcinoma (PDAC) represents a distinct entity with unique biology. The therapeutic impact of matched targeted therapy in these patients in…

Razelle Kurzrock, MD July 31, 2024

Outpatient Administration of CAR T-cell Therapies Using a Strategy of No Remote Monitoring and Early CRS Intervention – PubMed

Recent studies demonstrating the feasibility of outpatient chimeric antigen receptor modified (CAR) T-cell therapy administration are either restricted to CARs with 41BB costimulatory domains or…

Razelle Kurzrock, MD July 22, 2024

Survival Benefit Associated With Participation in Clinical Trials of Anticancer Drugs: A Systematic Review and Meta-analysis – PubMed

Many studies suggest a survival benefit for cancer trial participants. However, these benefits were not detected in studies using designs addressing important sources of bias…

Razelle Kurzrock, MD May 27, 2024

Related Articles